Notably, the study showed that the inhibition of aSMase reduced ceramide production and subsequently lipopolysaccharide (LPS)-induced periodontitis by reducing pro-inflammatory and pro-osteoclastogenic gene expression in macrophages in vitro and metabolic syndrome-induced periodontitis in vivo. Here, SMPD1 is linked to metabolic syndrome.